The treatment did not display significant side effects that are associated with other schizophrenia drugs.
BiolineRX Ltd. (TASE:BLRX) reported positive results from its phase IIa clinical trial for BL-1020, its schizophrenia drug. The drug was effective in reducing symptoms in the trial, and did not display significant side effects such as motor difficulty or weight gain, which are common side effects in existing schizophrenia drugs. BL-1020 is a drug based on a new formula. It was developed by professors at Bar- Ilan and Tel Aviv Universities. BiolineRX bought the marketing rights to those drugs from those universities. Last week, BioLineRX presented data from pre-clinical trials of another drug, BL-1021. Recent pre-clinical trials demonstrated that BL-1021 was safe and effective in pre-clinical testing for the treatment of neuropathic pain. "Based on the promising data presented here, we believe that BL-1021 has the potential to be a safe and effective drug for neuropathic pain, and we look forward to the initiation of the clinical trial program for this compound in 2008," stated Morris C. Laster, MD, chief executive officer of BioLineRx. "During the course of the year, we expect to significantly expand our clinical pipeline to a total of five therapeutic candidates."
Published by Globes [online], Israel business news - www.globes-online.com - on February 3, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008